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676Objective: Because microRNA-145 (miR-145) is a specific mediator in the regulation of the proliferation and
differentiation of smooth muscle cells, we investigated the effect of miR-145 on the intimal hyperplasia in the
rabbit model of vein graft disease using electroporation-mediated gene transfer.
Methods: The right jugular vein of male Japanese white rabbits was harvested and transduced with miR-145–
encoding plasmids using an electroporator and then interposed in the carotid artery. At 2 or 4 weeks postoper-
atively, the venous graft was explanted, and the intimal thickness and intima/media area ratio were evaluated.
Furthermore, 3 days after implantation, the myocardin and serum response factors were measured using real-
time polymerase chain reaction. At 2 weeks after implantation, immunohistochemical investigations using
mature smooth muscle markers, myosin heavy chain smooth muscle-1 and -2, and proliferation marker Ki-67
were performed.
Results:MiR-145 transduction significantly reduced the neointimal thickness at both 2 and 4 weeks (2 weeks,
52.1 15.7 vs 113.2 26.9 mm, P<.05, n¼ 6; 4 weeks, 42.4 4.8 vs 136.5 38.3 mm, P<.05, n¼ 8), and it
also significantly reduced the intima/media area ratio at 4 weeks (0.22  0.04 vs 1.13  0.23, P<.01, n ¼ 8).
Additionally, it upregulated the mRNA expression level of myocardin compared with that in the grafts that did
not receive gene transfer. Smooth muscle-2 and Ki-67 expression revealed that miR-145 transduced grafts con-
tained more smooth muscle-2–positive mature smooth muscle cells and fewer Ki-67–positive proliferating cells.
Conclusions: Nonviral transduction of miR-145 into the bypass graft could be a novel option for preventing
intimal hyperplasia in vein graft disease. (J Thorac Cardiovasc Surg 2014;148:676-82)Supplemental material is available online.The autologous vein graft has been widely used for revascu-
larization in coronary artery bypass grafting since its intro-
duction in 1969.1 Nevertheless, owing to accelerated
atherosclerosis, these vein grafts have had a lower patency
rate than those of other arterial grafts.2 Thrombotic occlu-
sion followed by intimal hyperplasia is the major cause of
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The Journal of Thoracic and Cardiovascular Surg(SMC) proliferation and migration into the intima are the
key mechanisms in this process. Chamley-Campbell and
colleagues3 first described the phenotypic modulation of
SMCs from the contractile state to the synthetic state.
Phenotypic alternations of vascular SMCs have been iden-
tified as playing an important role in the response to athero-
sclerosis, arterial injury, and bypass vein grafting.4-10 We
have previously demonstrated that C-type natriuretic
peptide suppressed neointimal lesion formation in the
arterialized rabbit vein graft model using adenovirus-
mediated gene transfer.11 We also reported that overexpres-
sion of C-type natriuretic peptide in SMCs induced growth
inhibition of proliferating SMCs, with alteration of the
phenotype from the synthetic state to the contractile state.12
MicroRNAs are a new class of small (22 nucleotides)
noncoding RNA. In most cases, microRNAs negatively
regulate expression of protein-coding genes by promoting
degradation or suppressing translation of target mRNAs
and modulating various biologic functions.13 Currently, mi-
croRNAs are under investigation as a new modality of gene
therapy for ischemic heart disease and vascular diseases.14
Recent studies have reported that microRNA-145 (miR-
145) is a specific mediator in the regulation of proliferation,
differentiation, and phenotype of SMCs and is necessary for
maintaining a differentiated SMC phenotype.4-7ery c August 2014
Abbreviations and Acronyms
GFP ¼ green fluorescent protein
miR-145 ¼ microRNA-145
SMC ¼ smooth muscle cell
SM-1 ¼ smooth muscle-1
SM-2 ¼ smooth muscle-2
SRF ¼ serum response factor
Ohnaka et al Evolving Technology/Basic ScienceIn recent years, electroporation-mediated gene transfer has
emerged in the in vivo study for future clinical applications
designed at overcoming virus-related problems.15 Therefore,
in the present study, we investigated the effect of miR-145 on
intimal hyperplasia in the rabbit model of vein graft disease
using electroporation-mediated gene transfer.E
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Animals
A total of 50 male Japanese white rabbits weighing 2.5 to 3.5 kg were
used. The rabbits were maintained with a 12-hour light/dark schedule
and fed a regular rabbit chow diet. The rabbits were randomly divided
into 2 groups: a control group (n ¼ 25) without electroporation-mediated
gene transfer and a miR-145 electroporation group (n ¼ 25). Three days
after the operation, 4 rabbits were killed for green fluorescent protein
(GFP) immunostaining and 5 rabbits for reverse transcriptase polymerase
chain reaction (PCR) study in each group. Another 8 rabbits from each
group were killed at 2 and 4 weeks after the initial histologic examination.
The Kyoto University animal experiment review board approved the pre-
sent experiment (approval reference no. MedKyo 12185). All the rabbits
were used in accordance with the guidelines for animal experiments of
Kyoto University, which conforms to the law of the ‘‘Guide for the Care
and Use of Laboratory Animals’’ in Japan.
Plasmid Preparation
Expression vector for human miR-145 (pMIW-cGFP-miR-145) was ob-
tained from B-Bridge Co, Ltd (Tokyo, Japan). In the construction of this
vector, a GFP expression site was included to confirm successful gene
transduction after electroporation (Appendix Figure 1).
Electric Pulse Delivery for Gene Electroporation
Electric pulses were delivered using an electric pulse generator (Super
Electroporator NEPA21, Nepa Gene Co, Ltd, Chiba, Japan). Figure 1, A,
shows a schematic representation of the electroporation device. Freshly iso-
lated vein grafts were suspended in balanced salt saline (140 mM NaCl, 5.4
mMKCl, and 10 mMHCL, pH 7.6) with 500 mg/mL of vector and placed in
an electrode chamber, as reported previously.16,17 First, to confirm the
validity of the electroporation method, we performed a preliminary in vitro
study using the DsRed expression vector in which several electric pulse
parameters were tested (‘‘poring pulse’’: voltage 25, 50, and 75 V; pulse
duration, 5 and 10 ms; interval, 95 and 90 ms; number of pulses, 2, 4, and
6; ‘‘transfer pulse’’: voltage, 10 V; pulse duration, 5 and 10 ms; interval,
95 and 90 ms; number of pulses, 5 and 10; Appendix Table 1). After electro-
poration, the grafts were suspended in a-minimal essential medium (Invitro-
gen, Carlsbad, Calif) supplemented with 10% fetal bovine serum
(Invitrogen) and 1% penicillin/streptomycin (Invitrogen), and cultured in
standard plastic dishes for 2 days. The grafts were observed using fluores-
cence microscopy and by immunostaining using monoclonal antibodies
against DsRed. Second, to decide on the optimal conditions for electropora-
tion, several electric pulse parameters were tested using the miR-145The Journal of Thoracic and Caexpression vector with a GFP expression site. These variables were chosen
on the basis of the results from our experiment using the DsRed expression
vector and earlier well-documented reports that used the electroporation
method.16-18 Finally, 2 electric poring pulses (25 V, 5-ms duration, 95-ms in-
terval) followed by 8 transfer pulses (10 V, 5-ms duration, 95-ms interval)
were adopted according to the results of both DsRed and GFP apparent
expression shown in Appendix Figure 2 and Figure 1, C.
Arterialized Rabbit Vein Graft Model
The operative procedurewas performed under aseptic conditions. Anes-
thesia was achieved by administration of pentobarbital sodium (25 mg/kg
intravenously) and lidocaine hydrochloride (50 mg/kg subcutaneously).
After a longitudinal neck incision, a 15- to 20-mm segment of the right ju-
gular vein was exposed, and all the branches of the vein were ligated. A 2F
Fogarty balloon catheter was inserted. After the balloon was inflated with
0.2 mL of air, the intima of the vein was denuded by 3 passages of the cath-
eter. The vein was removed and kept moistened in heparinized saline (10
IU/mL) at room temperature. After the rabbits had been given intravenous
heparin (200 IU/kg), a 15- to 20-mm segment of the common carotid artery
was meticulously isolated with vascular forceps and then removed. The
prepared vein graft was interposed in the carotid artery in a reversed
end-to-end fashion. Anastomoses were created with 10-0 nylon continuous
suture under 310 magnification using an operative microscope. To facili-
tate the intimal hyperplasia, the internal carotid artery and one of the
branches of the external carotid artery were ligated with 6-0 silk suture.
The wound was closed layer to layer. Cefazolin sodium was given intrave-
nously as a prophylactic measure.
Intimal Hyperplasia Assessment
At 2 or 4 weeks after the operation, the vein grafts were harvested under
general and local anesthesia, and the rabbits were killed by an overdose of
pentobarbital sodium. The harvested vein grafts were fixed with 10%
phosphate-buffered formalin at a pressure of 100 mm Hg for 20 minutes.
The perfused vein graft was immersed in the same fixative overnight and
subjected to histologic examination. At least 4 sections were obtained
from each vein graft and stained with both hematoxylin and eosin and elas-
tica van Gieson. The neointima was defined as the area from the inner sur-
face to the internal elastic lamina. The cross-sectional intimal thickness
was measured at 6 randomly selected views per section. The average of
the 6 values was used to represent intimal hyperplasia. The cross-
sectional intima/media area ratio was also calculated.
Immunohistochemical Staining
At 3 days postoperatively, the vein grafts were explanted, and GFP im-
munostaining was performed to confirm the gene transduction of miR-145
using the electroporation method. At 2 weeks postoperatively, the vein
grafts were explanted and analyzed by immunostaining using monoclonal
antibodies against myosin heavy chain smooth muscle-1 (SM-1) and
smooth muscle-2 (SM-2; Yamasa Corp, Tokyo, Japan). SM-1 is constitu-
tively expressed in all types of adult SMCs, but SM-2 exists only in mature
differentiated SMCs.8-10 Additionally, immunohistochemical staining with
Ki-67 monoclonal antibody (DAKO Cytomation, Glostrup, Denmark) was
performed to identify the proliferative cells in the neointima. The quantita-
tive analysis was performed as follows. The total and Ki-67–positive cells
were counted in 8 randomly selected high-power fields (original magnifi-
cation, 3400) per section, and the number of Ki-67–positive cells/total
number of cells counted was defined as the Ki-67 index.
Quantitative Real-Time PCR Analysis
At 3 days after implantation, the vein grafts were explanted and pre-
served immediately in liquid nitrogen. Total RNA was then extracted
from the vein using the RNeasyMini Kit (Qiagen, Venlo, The Netherlands)
and reverse transcribed with the SuperScript III First-Strand Synthesisrdiovascular Surgery c Volume 148, Number 2 677
FIGURE 1. A, Schematic illustration of the electroporation device and representative photographs of green fluorescent protein immunostaining 3 days after
implantation. B, Control and C, microRNA-145 (scale bar, 100 mm). Green fluorescent protein–positive cells were detected in the media of the microRNA-
145–transduced grafts.
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Calif) in accordance with the manufacturer’s instructions. Real-time PCR
was performed on the StepOnePlus Real-Time PCR System (Applied Bio-
systems, Oakville, Ontario, Canada) using the SybrGreen quantitative PCR
Mastermix (Qiagen). Custom-designed primers for rabbit serum response
factor ([SRF] 50-CCACGGACCAGAGAATGAGT-30 and 50-
GGCTTCAGTGTGTCCTTGGT-30) and myocardin (50-GCATCACG-
GATGGATTCTCT-30 and 50-ACTGCAGCCCATTACTGTCC-30) were
purchased from Life Technologies Japan, Ltd (Tokyo, Japan). The gene
expression data were analyzed using the relative standard curve method.
The expression level of mRNA was divided by the mRNA level of the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase.
Statistical Analysis
All values are presented as the mean  standard error. The data were
evaluated using an unpaired Student t test using Statview software,
version 5.0 (SAS Institute, Cary, NC).RESULTS
GFP Immunostaining
At 3 days after implantation, several GFP-positive stain-
ing areas were detected in the media of the miR-145–trans-
duced graft, indicating successful gene transduction of
miR-145 into the bypass grafts using the electroporation
method (Figure 1, B and C).Intimal Hyperplasia
As shown in Figure 2,A, in the arterialized vein grafts at 4
weeks postoperatively, the control grafts had formed a thick
neointima. In contrast, the miR-145–transduced grafts
showed much thinner neointimal lesions. The statistical678 The Journal of Thoracic and Cardiovascular Surganalysis of the cross-section demonstrated that the intima/
media area ratio of the miR-145–transduced group was
significantly lower than that of the control group (2 weeks,
0.31 0.06 vs 1.25 0.18, P<.01, n¼ 6; 4 weeks, 0.22
0.04 vs 1.13  0.23, P<.01, n ¼ 8; Figure 2, B).
Figure 2, C, shows the comparison of the neointimal
lesion thickness at 2 and 4 weeks after implantation in
each group. The intimal thickness was significantly lower
in the miR-145–transduced group at both 2 and 4 weeks af-
ter implantation (2 weeks, 52.1 15.7 vs 113.2 26.9 mm,
P<.05, n ¼ 6; 4 weeks, 42.4  4.8 vs 136.5  38.3 mm,
P<.05, n ¼ 8).
Immunohistochemical Staining for SM-1 and -2
At 2 weeks after implantation, smooth muscle marker
SM-1 immunostaining was detected equally in both control
and miR-145–transduced vein grafts. Staining for SM-2, a
mature SMC marker, revealed that the SM-2–positive area
was barely detectable in the neointima of the control grafts,
but SM-2 was positive in the reduced neointimal lesion of
the miR-145–transduced grafts (Figure 3).
Immunohistochemical Staining for Ki-67
Figure 4,A andB, illustrates the Ki-67–positive cells in the
neointimal lesion of the grafts 2 weeks after implantation.
The frequency of Ki-67–positive cells was much greater in
the control grafts. The Ki-67 index was significantly greater
in the control group than in the miR-145–transduced group
(11.1 1.0 vs 23.2  1.3, n ¼ 2).ery c August 2014
FIGURE 2. A, Representative photographs of vein grafts 4 weeks after implantation. Elastica van Gieson staining. Arrowheads indicate the internal elastic
lamina (scale bar, 100 mm). B, Cross-sectional intima/media area ratio 4 weeks after implantation. C, Intimal thickness 2 and 4 weeks after implantation
(*P<.05). Neointimal lesion formation was significantly suppressed in the miR-145–transduced group 2 and 4 weeks after implantation. miR-145, micro-
RNA-145.
Ohnaka et al Evolving Technology/Basic ScienceQuantitative Real-Time PCR for Myocardin and
SRF
The mRNA expression of myocardin was significantly
upregulated in the miR-145–transduced grafts compared
with the control grafts 3 days postoperatively (2.03 
0.99 vs 0.90  0.46, P< .001, n ¼ 5). In contrast, the
mRNA expression level of SRF did not reach a statistically
significant difference between the miR-145–transducedFIGURE 3. Smooth muscle (SM)-1 and SM-2 immunostaining of the vein gra
(scale bar, 100 mm). Staining for SM-2, a mature smooth muscle cell marker, rev
the control grafts, but SM-2 was positive in the reduced neointimal lesion of th
The Journal of Thoracic and Cagrafts and the control grafts 3 days postoperatively
(Figure 5, A and B).
DISCUSSION
The results of the present study have demonstrated that
miR-145–transduced vein grafts inhibited neointimal lesion
formation compared with the control grafts in the arterial-
ized rabbit vein graft model. To our knowledge, this is thefts 2 weeks after implantation. Arrowheads indicate internal elastic lamina
ealed that the SM-2–positive area was barely detectable in the neointima of
e microRNA-145–transduced grafts.
rdiovascular Surgery c Volume 148, Number 2 679
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FIGURE 4. Ki-67 immunostaining of the vein grafts 2 weeks after implantation. A, Control. B, microRNA-145.White arrowheads indicate Ki-67–positive
cells; dashed line, internal elastic lamina (scale bar, 50 mm). The frequency of Ki-67–positive cells was much greater in the control grafts, suggesting more
proliferative cells were present in the control group.
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Sfirst report on the introduction of miR-145, which specif-
ically regulates the SMC phenotype, to vein graft disease
in rabbit using a nonviral gene transfer method.
Previously, Cordes and colleagues5 had demonstrated the
ability of miR-145 to efficiently direct the differentiation of
vascular SMCs using transgenic mice experiments. They
showed that miR-145 promotes the differentiation and re-
presses the proliferation of SMCs.5 Our present study was
based on their hypothesis that the restoration of miR-145
possibly suppresses the smooth muscle hyperplasia
observed with vascular injury and atherosclerosis.
Cheng and colleagues4 revealed in their in vitro and
invivo studies thatmiR-145was a vascular SMCphenotypic
modulator that controlled the formation of vascular neointi-
mal lesions. They demonstrated that, using balloon-injured
rat arteries, the differentiation of vascular SMCs was accel-
erated by an adenovirus vector expressing miR-145.4
We recently revealed the essential function of miR-145 in
the differentiation process of SMCs from undifferentiated
human embryonic stem cells. Overexpression of miR-145
in the embryonic stem cell–derived precursor of SMCsFIGURE 5. A, Serum response factor and B, myocardin mRNA expression
polymerase chain reaction 3 days postoperatively. ThemRNAexpression level of
grafts (2.03  0.99 vs 0.90  0.46, P<.001, n ¼ 5).
680 The Journal of Thoracic and Cardiovascular Surg(ES-pre-SMCs) accelerated SMC differentiation, which
was confirmed by analysis of smooth muscle marker
expression, morphologic changes, and contractile func-
tion.7 From these findings, we believe that miR-145 works
as an essential regulator for SMC differentiation.
Although various protein-based signaling cascades have
been implicated in controlling the SMC phenotype,11,12,19
applying microRNA to vascular SMCs shows great
potential owing to the manner in which it functions. The
key characteristic of microRNA is its ability to regulate
the expression of multiple genes, because it can bind to a
number of mRNA targets.13 Cordes and colleagues5 re-
vealed that miR-145 targeted a network of smooth
muscle-related transcription factors, including Kruppel-
like factor 4, myocardin, and Elk-1 (a member of the ETS
oncogene family), which can promote the differentiation
and repress the proliferation of SMCs.
Among these factors, myocardin is a cardiac and smooth
muscle-specific factor for SMC differentiation that was
discovered by Wang and colleagues.20 They subsequently
recognized that myocardin was a master regulator ofin explanted grafts were evaluated by quantitative reverse transcriptase-
myocardinwas significantly upregulated in themicroRNA-145–transduced
ery c August 2014
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is also a component of a molecular switch for the SMCs’
fate, which is sufficient for it to affect both the structural
and the physiologic attributes of this cell type. SRF weakly
activated the miR-143/145 enhancer upstream of a lucif-
erase reporter but co-transfection of myocardin synergisti-
cally and robustly activated luciferase activity.5
From these findings, although numerous factors and co-
factors are concerned with SMC differentiation, we believe
miR-145 has additive and synergic effects on its down-
stream factors for differentiation.
To date, many investigators have presented the results of
procedures that inhibit vein graft disease in animal
models.11,12,19,22-24 Nevertheless, none of these methods
can be applied to clinical research or usage, because they
use virus-mediated gene transduction. For example, the
use of adenoviral vectors is one of the most popular
methods in virus-mediated gene transfer. Its procedures
have been already established, and its efficacy of gene trans-
duction has been considered satisfactory.11,12,19,23,24
However, ethical issues and cytotoxicity remain owing to
difficulties in virus handling and regulation. We recently
documented the 3 goals that need to be achieved for
clinical usage in gene therapy: suitable vectors, suitable
genes, and an appropriate delivery system.25 In the present
study, we chose the electroporation method to overcome
virus-related problems and establish an appropriate delivery
system for clinical application. Eefting and colleagues15
also chose electroporation-mediated gene transfer in their
mouse arterial bypass model, resulting in the effective
in vivo suppression of vein graft disease. However, the effi-
cacy of gene transduction using the electroporation method
is controversial. In addition, electroporation is not without
its disadvantages, with heat injury being the most common
problem. Previously, Matsumoto and colleagues18 estab-
lished the optimal settings of in vivo gene transfer to the rab-
bit carotid artery using an electric pulse. They found that
transgene expression was increased in nearly a voltage-
dependent manner 20 V; however, administration at>30
V resulted in a marked decrease of cells in the arterial
wall owing to apoptosis induced by electroporation.18 Simi-
larly, we observed vacuolar degeneration and the disappear-
ance of nuclei in the vasculature after high-energy delivery
to the vein grafts (Appendix Table 2 and Appendix
Figure 3). Thereafter, Yamaoka and colleagues16 estab-
lished the optimal parameters for gene transfer into the rab-
bit vein graft model (pulse-on time, 5 ms; interval time, 95
ms; number of pulses, 10; voltage, 10 V [from the inner
lumen side] and 30 V [from the adventitia side]). On the ba-
sis of their method, we modified these parameters in our ex-
periments. Our electroporation device has mainly 2
characteristics: ‘‘poring pulse’’ and ‘‘transfer pulse.’’ The
former is for creating temporary pores (small holes) in the
cell membranes with minimal damage and the latter forThe Journal of Thoracic and Cadelivering the target molecules into cells with minimal
damage. On the basis of the established optimal settings
of electroporation16-18 and taking both our histologic
findings and the distinguishing characteristics of the
electric device into account, we adapted the former
documented duration (5 ms) and interval time (95 ms)
using a decrease in the number of poring pulses and an
increase in the number of transfer pulses. Thus, we were
able to achieve the successful gene transduction of miR-
145 (Figure 1, C).
SMC proliferation and migration into the intima are the
key mechanisms in the pathogenesis of atherosclerosis
and vein graft disease after surgical revascularization. Na-
gai and colleagues8 have demonstrated that smooth muscle
myosin heavy chain isoforms are useful markers for
vascular SMC differentiation. In the present study, many
more SM-2–positive mature SMCs were present in the
miR-145–transduced grafts than in the control grafts, indi-
cating that the dedifferentiation of SMCs was inhibited.
Because Ki-67–positive cells were observed more
frequently in the control grafts than in the miR-145–
transduced grafts, it was determined that the neointima of
the control grafts contained a significant number of prolifer-
ative cells. From these observations, we speculated that
these cells originated from a synthetic phenotype of
SMCs because the control grafts did not contain mature
SM-2–positive cells. We, therefore, believe that prolifera-
tion of the synthetic phenotype was inhibited in the
miR-145–transduced grafts compared with that in the con-
trol grafts. This is consistent with the theory from Elia and
colleagues,6 who asserted that miR-145 gene expression
functioned as a brake to dedifferentiation rather than as a
stimulus for differentiation.
The precise mechanisms of the function of miR-145
should be clarified, and additional investigation is needed.
We believe that downstream factors such as Kruppel-like
factor 4 and Elk-1 would be good candidates for future
study.
CONCLUSIONS
The results of our present study have demonstrated that
nonviral transduction of miR-145, which specifically regu-
lates the SMC phenotype, into the bypass graft inhibits neo-
intimal lesion formation and could be a novel option to
prevent vein graft disease after surgical revascularization.
We would like to thank Dr Tsuruyama, Department of Diag-
nostic Pathology, Kyoto University Graduate School of Medicine,
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Cardiovascular Surgery, Kyoto University Graduate School of
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APPENDIX FIGURE 1. Schema of the construct of the microRNA-145
(miRNA-145) expression vector, which included microRNA-145 and a
green fluorescent protein expression site.
APPENDIX FIGURE 2. Left, DsRed fluorescent image and Right, DsRed immunostaining 2 days after electroporation (original magnification3200). Lu,
Lumen side; Ad, adventitia side. Apparent DsRed expression in the lumen side was observed, indicating successful gene transduction after adopting the
electric parameters of sample 4 (Appendix Table 1).
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APPENDIX FIGURE 3. Representative photographs of degenerative vasculature in the preliminary in vivo study using a microRNA-145 expression vec-
tor. Electric parameters are described in Appendix Table 2. The vein grafts were explanted 2 weeks after implantation (hematoxylin and eosin staining). Lu,
Lumen side;Ad, adventitia side. A,Black arrowheads indicate the vacuolar degeneration in the vasculature (original magnification3100). B, Betweenwhite
arrowheads, the disappearance of nuclei was observed in almost all layers of the vasculature (original magnification 3200).
APPENDIX TABLE 1. Four examples of>20 settings of 4 electric parameters in a preliminary in vitro study using a DsRed expression vector
‘‘Poring pulse’’ ‘‘Transfer pulse’’
Total
energy (J)Vol (V) Dur (ms) Int (ms) Freq (n)
Delivered
energy (J) Vol (V) Dur (ms) Int (ms) Freq (n)
Delivered
energy (J)
Control — — — — — — — — — — —
Sample 1 25 5 50 2 0.306 10 5 95 10 0.034 0.340
Sample 2 4 0.425 5 95 10 0.036 0.461
Sample 3 4 0.478 10 90 10 0.066 0.544
Sample 4 6 0.626 10 90 5 0.070 0.695
Vol, Voltage; Dur, pulse duration; Int, interval time; Freq, number of pulses.
APPENDIX TABLE 2. Electric parameters in a preliminary in vivo study using a microRNA-145 expression vector based on the in vitro study
using a DsRed expression vector
‘‘Poring pulse’’ ‘‘Transfer pulse’’
Total
energy (J)Vol (V) Dur (ms) Int (ms) Freq (n)
Delivered
energy (J) Vol (V) Dur (ms) Int (ms) Freq (n)
Delivered
energy (J)
miR-145 25 5 50 6 0.832 10 10 90 5 0.090 0.922
Vol, Voltage; Dur, pulse duration; Int, interval time; Freq, number of pulses.
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